Recent Updates
Recently added Catalysts

PI3K inhibitor BKM120

Phase 3

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Small Molecules | Oncology |Novartis AG|Trials Updated: Jun 30, 2022

PI3K inhibitor BKM120 development status

Highest phase Phase 3 (NCT01610284)
Phase scored for NVSPhase 1
Registered trials 31 across 13 sponsors since Feb 2010

PI3K inhibitor BKM120 target and mechanism

ModalitySmall Molecules

Also known as BKM120

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment18

FDA Designations

No designations recorded

PI3K inhibitor BKM120 clinical trials

PI3K inhibitor BKM120 · 1 trial · 9 indications

Phase 1 1
NCT02049541Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
COMPLETED18 Analytics
PHASE1COMPLETED
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueUnlock trial analytics

Study Endpoints

Primary Endpoints

MTD defined as the dose level at which no more than one of 6 patients experiences a DLT summarized using the National Cancer Institute (NCI) CTCAE version 4.0
28 days

Summarized and tabulated by dose level.

Secondary Endpoints

Incidence of grade 3 or greater adverse events summarized using the NCI CTCAE version 4.0
Up to 5 years
Overall response rate (ORR) evaluated by computed tomography (CT) or positron emission tomography (PET)/CT
Up to 5 years
Change in correlative markers in blood, bone marrow and tumor tissue
Baseline to up to 5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treatment (PI3K inhibitor BKM120, rituximab)EXPERIMENTALPatients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.

Interventions

NameTypeDescription
PI3K inhibitor BKM120DRUGWill be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
rituximabBIOLOGICALGiven IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
PharmacodynamicsOTHERPharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
Correlative studiesOTHERPatients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Patients must have histologically confirmed indolent B-cell NHL or mantle cell lymphoma; acceptable subtypes of indolent B-cell NHL include follicular lymphoma (grades 1, 2, or 3a), marginal zone lymphoma, or lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia; patients...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about PI3K inhibitor BKM120

What is PI3K inhibitor BKM120?

PI3K inhibitor BKM120 is an investigational small molecule developed by Novartis AG for certain B-cell lymphomas. It has been studied in a Phase 1 trial in adults with relapsed or refractory indolent B-cell lymphoma, including extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. It is not an approved therapy.

What is PI3K inhibitor BKM120 used for?

PI3K inhibitor BKM120 has been studied in adults with relapsed or refractory indolent B-cell lymphomas, including extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, splenic marginal zone lymphoma, and Waldenström macroglobulinemia. It is investigational and has not been approved for any indication.

Who makes PI3K inhibitor BKM120?

PI3K inhibitor BKM120 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis sponsored the Phase 1 study of BKM120 given with rituximab in patients with relapsed or refractory indolent B-cell lymphoma.

What phase is PI3K inhibitor BKM120 in?

PI3K inhibitor BKM120 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 18 participants and was an uncontrolled, non-randomized, open-label study, so it did not include a placebo or comparator arm.

What clinical trials is PI3K inhibitor BKM120 in?

PI3K inhibitor BKM120 has been evaluated in one completed Phase 1 trial, NCT02049541, titled Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma. The trial enrolled 18 adults aged 18 years and older in the United States and combined BKM120 with rituximab.